Fundamentals Overview
HCA Healthcare, Inc. is in the middle of its 52-week range with attractive valuation, trending downward today.
Valuation attractive
Intrinsic value (DCF)
-41% downside vs price
Profitability
Risk (Beta)
1.37 — higher vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Analyst grade: B- · 3M vs Healthcare sector: +9.1%
Pressures (Sell):
DCF 41% downside vs price · Sentiment weakening (1 downgrade) · Beta 1.37 (elevated)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B-. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 11, Equal Weight: 3, Neutral: 2, Outperform: 7, Overweight: 6, Underweight: 1.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $288.23; current price is $488.58. That’s a -41% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 16.62 |
| DCF value (model) | $288.23 (-41% vs price) |
| PEG (TTM) | 0.93 |
| P/B (TTM) | N/A |
| P/S (TTM) | 1.45 |
| P/FCF (TTM) | 14.2 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 0.83 |
| Quick Ratio (TTM) | 0.73 |
| Cash Ratio (TTM) | 0.06 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 8.97% |
| Gross margin (TTM) | 41.5% |
| Operating margin (TTM) | 15.83% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for HCA.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| TD Cowen | maintain | Buy | Buy | 2026-03-10 |
| Mizuho | maintain | Outperform | Outperform | 2026-02-25 |
| UBS | maintain | Buy | Buy | 2026-02-23 |
| JP Morgan | maintain | Neutral | Neutral | 2026-02-20 |
| Argus Research | maintain | Buy | Buy | 2026-02-06 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2026-01-30 |
| Keybanc | maintain | Overweight | Overweight | 2026-01-28 |
| Truist Securities | maintain | Buy | Buy | 2026-01-28 |
| RBC Capital | maintain | Outperform | Outperform | 2026-01-28 |
| Cantor Fitzgerald | maintain | Overweight | Overweight | 2026-01-28 |
| Oppenheimer | maintain | Outperform | Outperform | 2026-01-28 |
| Deutsche Bank | maintain | Buy | Buy | 2026-01-28 |
| Barclays | maintain | Overweight | Overweight | 2026-01-28 |
| UBS | maintain | Buy | Buy | 2026-01-28 |
| Jefferies | maintain | Buy | Buy | 2026-01-28 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2026-01-07 |
| Mizuho | maintain | Outperform | Outperform | 2025-12-18 |
| Morgan Stanley | downgrade | Equal Weight | Underweight | 2025-12-15 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2025-11-13 |
| Jefferies | maintain | Buy | Buy | 2025-10-28 |
| Oppenheimer | maintain | Outperform | Outperform | 2025-10-27 |
| Barclays | maintain | Overweight | Overweight | 2025-10-27 |
| Keybanc | maintain | Overweight | Overweight | 2025-10-27 |
| B of A Securities | maintain | Neutral | Neutral | 2025-10-27 |
| Stephens & Co. | maintain | Overweight | Overweight | 2025-10-27 |
| Mizuho | maintain | Outperform | Outperform | 2025-10-27 |
| Goldman Sachs | maintain | Buy | Buy | 2025-10-27 |
| Truist Securities | maintain | Buy | Buy | 2025-10-27 |
| RBC Capital | maintain | Outperform | Outperform | 2025-10-27 |
| UBS | maintain | Buy | Buy | 2025-10-27 |